| Identification | More | [Name]
THIONICOTINAMIDE | [CAS]
4621-66-3 | [Synonyms]
3-PYRIDYLTHIOCARBOXAMIDE
AKOS B028584
ART-CHEM-BB B028584
PYRIDINE-3-CARBOTHIOAMIDE
PYRIDINE-3-CARBOTHIOIC ACID AMIDE
PYRIDINE-3-THIOAMIDE
THIONICOTINAMIDE
3-pyridinecarbothioamide
3-pyridinethiocarboxamide
3-pyridylthioformamide
3-thioamidopyridine
3-thiocarbamoylpyridine
nicotinothioamide
thio-3-pyridinecarboxamide
thio-nicotinamid
Pyridine-3-thiocarboxamide
Thionicotinamide,98%
PYRIDINE-3-THIOCARBOXAMIDE (THIONICOTINAMIDE)
Nicotinthioamide | [EINECS(EC#)]
225-036-6 | [Molecular Formula]
C6H6N2S | [MDL Number]
MFCD00006399 | [Molecular Weight]
138.19 | [MOL File]
4621-66-3.mol |
| Chemical Properties | Back Directory | [Appearance]
yellow powder | [Melting point ]
185-190 °C
| [Boiling point ]
278.9±32.0 °C(Predicted) | [density ]
1.235 (estimate) | [refractive index ]
1.5300 (estimate) | [Fp ]
160 °C
| [storage temp. ]
Inert atmosphere,Room Temperature | [form ]
Powder | [pka]
12.01±0.29(Predicted) | [color ]
Yellow to yellow-green | [Detection Methods]
HPLC,NMR | [BRN ]
109593 | [InChI]
InChI=1S/C6H6N2S/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9) | [InChIKey]
XQWBMZWDJAZPPX-UHFFFAOYSA-N | [SMILES]
C1=NC=CC=C1C(N)=S | [LogP]
0.670 | [CAS DataBase Reference]
4621-66-3(CAS DataBase Reference) | [EPA Substance Registry System]
3-Pyridinecarbothioamide (4621-66-3) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S24/25:Avoid contact with skin and eyes .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [RTECS ]
QS4488000 | [TSCA ]
Yes | [HazardClass ]
IRRITANT | [HS Code ]
29333990 |
| Hazard Information | Back Directory | [Chemical Properties]
yellow powder | [Definition]
Thionicotinamide is the active moiety of two previously identified NADK inhibitors, NADS and NADPS. Treatment of C85 cancer cells with thionicotinamide resulted in an identical loss of dihydrofolate reductase levels, a G1/S block, and similar toxicity profiles as NADS and NADPS; that is, thionicotinamide is a prodrug and is converted intracellularly to NADPS[1].
| [References]
[1] Philip M Tedeschi. “Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy.” Molecular Pharmacology 88 4 (2015): 720–7.
|
|
|